Xtl Biopharmaceuticals (XTLB) Receivables (2009 - 2025)
Xtl Biopharmaceuticals (XTLB) posted quarterly Receivables of $121000.0 for Q4 2025, down 38.58% year-on-year from $197000.0 in Q4 2024, and down 38.58% on a QoQ basis from $197000.0 in Q4 2024.
Xtl Biopharmaceuticals (XTLB) Receivables (2009 - 2025) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Receivables for 11 consecutive years, with $121000.0 the latest figure, recorded in Q4 2025.
- Quarterly Receivables fell 38.58% year-over-year to $121000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $121000.0 (down 38.58% YoY) and the FY2025 annual result came in at $121000.0, down 38.58% from the prior year.
- Receivables eased to $121000.0 in Q4 2025 per XTLB's latest filing, from $197000.0 in the prior quarter.
- Over the last five years, Receivables for XTLB reached as high as $8.1 million in Q4 2021 and fell as low as $121000.0 in Q4 2025.
- A 5-year average of $4.9 million and a median of $8.0 million in 2023 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables dropped 0.31% — and 2024, when it sank 97.55%.
- Year by year, Receivables stood at $8.1 million in 2021, then decreased by 0.31% to $8.1 million in 2022, then dropped by 0.56% to $8.0 million in 2023, then plunged by 97.55% to $197000.0 in 2024, then plunged by 38.58% to $121000.0 in 2025.
- According to Business Quant data, Receivables over the past three periods registered $121000.0, $197000.0, and $8.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | 121,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 121,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Dec 31, 2023 | 8.04 Mn |
| Dec 31, 2022 | 8.09 Mn |
| Dec 31, 2021 | 8.11 Mn |
| Sep 30, 2014 | 750,000.00 |
| Jun 30, 2014 | 675,000.00 |
| Mar 31, 2014 | 688,000.00 |
| Dec 31, 2013 | 599,000.00 |
| Sep 30, 2013 | 973,000.00 |
| Jun 30, 2013 | 265,000.00 |
| Mar 31, 2013 | 265,000.00 |
| Dec 31, 2012 | 229,000.00 |
| Sep 30, 2012 | 178,000.00 |
| Jun 30, 2012 | 205,000.00 |
| Mar 31, 2012 | 162,000.00 |
| Dec 31, 2011 | 136,000.00 |
| Sep 30, 2011 | 49,000.00 |
| Jun 30, 2011 | 59,000.00 |
| Mar 31, 2011 | 92,000.00 |